UA122117C2 - Способи лікування патологічних станів ока за допомогою імплантату з довготривалою доставкою лікарської речовини - Google Patents
Способи лікування патологічних станів ока за допомогою імплантату з довготривалою доставкою лікарської речовини Download PDFInfo
- Publication number
- UA122117C2 UA122117C2 UAA201605224A UAA201605224A UA122117C2 UA 122117 C2 UA122117 C2 UA 122117C2 UA A201605224 A UAA201605224 A UA A201605224A UA A201605224 A UAA201605224 A UA A201605224A UA 122117 C2 UA122117 C2 UA 122117C2
- Authority
- UA
- Ukraine
- Prior art keywords
- eye
- implant
- biodegradable
- biodegradable implant
- zhk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361904887P | 2013-11-15 | 2013-11-15 | |
| PCT/US2014/065804 WO2015073895A1 (en) | 2013-11-15 | 2014-11-14 | Methods of treatment of ocular conditions with a sustained drug delivery implant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA122117C2 true UA122117C2 (uk) | 2020-09-25 |
Family
ID=52001114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201605224A UA122117C2 (uk) | 2013-11-15 | 2014-11-14 | Способи лікування патологічних станів ока за допомогою імплантату з довготривалою доставкою лікарської речовини |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20150140062A1 (enExample) |
| EP (2) | EP3068403B2 (enExample) |
| JP (2) | JP6675307B2 (enExample) |
| KR (3) | KR20240058976A (enExample) |
| CN (1) | CN105764517A (enExample) |
| AU (4) | AU2014348369B2 (enExample) |
| CA (1) | CA2929689A1 (enExample) |
| CL (1) | CL2016001167A1 (enExample) |
| CY (1) | CY1123344T1 (enExample) |
| DK (1) | DK3068403T3 (enExample) |
| ES (1) | ES2819215T3 (enExample) |
| HU (1) | HUE050913T2 (enExample) |
| IL (2) | IL245548A0 (enExample) |
| MX (2) | MX2016006334A (enExample) |
| MY (1) | MY176039A (enExample) |
| NZ (1) | NZ719953A (enExample) |
| PH (1) | PH12016500869B1 (enExample) |
| PL (1) | PL3068403T3 (enExample) |
| PT (1) | PT3068403T (enExample) |
| RU (1) | RU2690841C1 (enExample) |
| SG (1) | SG10201809363SA (enExample) |
| SI (1) | SI3068403T1 (enExample) |
| UA (1) | UA122117C2 (enExample) |
| WO (1) | WO2015073895A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6914931B2 (ja) * | 2015-07-23 | 2021-08-04 | アエリエ ファーマシューティカルズ インコーポレイテッド | 眼の症状の治療のための医薬組成物、硝子体内インプラント及び医薬品の製造におけるそれらの使用 |
| JP2019534063A (ja) | 2016-09-02 | 2019-11-28 | エンビシャ セラピューティクス インコーポレイテッド | インプラントアプリケータ |
| CN111971026A (zh) | 2018-05-24 | 2020-11-20 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| BR112020023982A2 (pt) | 2018-05-24 | 2021-02-23 | Celanese Eva Performance Polymers Llc | dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular |
| KR20230041708A (ko) * | 2020-07-16 | 2023-03-24 | 오큘라 테라퓨틱스, 인코포레이티드 | 글루코코르티코이드를 함유하는 안구 삽입물 |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| AU3649502A (en) | 2000-11-29 | 2002-06-11 | Oculex Pharm Inc | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US8685435B2 (en) * | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| US20090082321A1 (en) * | 2007-09-21 | 2009-03-26 | Allergan, Inc. | Steroid containing drug delivery systems |
| WO2012109673A1 (en) * | 2011-02-11 | 2012-08-16 | Psivida Us, Inc. | Methods of treating macular edema using antiedema therapeutics |
-
2014
- 2014-11-14 EP EP14805768.0A patent/EP3068403B2/en active Active
- 2014-11-14 DK DK14805768.0T patent/DK3068403T3/da active
- 2014-11-14 HU HUE14805768A patent/HUE050913T2/hu unknown
- 2014-11-14 PT PT148057680T patent/PT3068403T/pt unknown
- 2014-11-14 KR KR1020247013455A patent/KR20240058976A/ko not_active Ceased
- 2014-11-14 CA CA2929689A patent/CA2929689A1/en active Pending
- 2014-11-14 NZ NZ719953A patent/NZ719953A/en not_active IP Right Cessation
- 2014-11-14 PL PL14805768T patent/PL3068403T3/pl unknown
- 2014-11-14 EP EP20173457.1A patent/EP3714875A1/en active Pending
- 2014-11-14 MX MX2016006334A patent/MX2016006334A/es unknown
- 2014-11-14 KR KR1020227018854A patent/KR20220082934A/ko not_active Ceased
- 2014-11-14 RU RU2016119132A patent/RU2690841C1/ru active
- 2014-11-14 KR KR1020167015466A patent/KR102475746B1/ko active Active
- 2014-11-14 MY MYPI2016000899A patent/MY176039A/en unknown
- 2014-11-14 ES ES14805768T patent/ES2819215T3/es active Active
- 2014-11-14 UA UAA201605224A patent/UA122117C2/uk unknown
- 2014-11-14 US US14/542,189 patent/US20150140062A1/en not_active Abandoned
- 2014-11-14 CN CN201480062403.7A patent/CN105764517A/zh active Pending
- 2014-11-14 SG SG10201809363SA patent/SG10201809363SA/en unknown
- 2014-11-14 SI SI201431652T patent/SI3068403T1/sl unknown
- 2014-11-14 JP JP2016530991A patent/JP6675307B2/ja active Active
- 2014-11-14 AU AU2014348369A patent/AU2014348369B2/en active Active
- 2014-11-14 WO PCT/US2014/065804 patent/WO2015073895A1/en not_active Ceased
-
2016
- 2016-05-09 IL IL245548A patent/IL245548A0/en unknown
- 2016-05-11 PH PH12016500869A patent/PH12016500869B1/en unknown
- 2016-05-13 CL CL2016001167A patent/CL2016001167A1/es unknown
- 2016-05-13 MX MX2022002306A patent/MX2022002306A/es unknown
-
2019
- 2019-12-13 JP JP2019225503A patent/JP7022735B2/ja active Active
-
2020
- 2020-06-30 AU AU2020204362A patent/AU2020204362A1/en not_active Abandoned
- 2020-09-14 CY CY20201100867T patent/CY1123344T1/el unknown
-
2022
- 2022-02-23 IL IL290837A patent/IL290837A/en unknown
- 2022-06-29 AU AU2022204607A patent/AU2022204607A1/en not_active Abandoned
-
2024
- 2024-08-09 AU AU2024205640A patent/AU2024205640B2/en active Active
-
2025
- 2025-02-21 US US19/060,301 patent/US20250319031A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Habot‐Wilner et al. | Suprachoroidally injected pharmacological agents for the treatment of chorio‐retinal diseases: a targeted approach | |
| AU2024205640B2 (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| JP6132964B2 (ja) | 萎縮性加齢性黄斑変性の処置方法 | |
| RU2641021C2 (ru) | Имплантат для пролонгированной доставки лекарственного средства | |
| Bandello et al. | Update of intravitreal steroids for the treatment of diabetic macular edema | |
| Jain et al. | Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results | |
| de Oliveira Dias et al. | New drugs and new posterior delivery methods in CME | |
| Jahangir et al. | Evaluation of the effect of suprachoroidal triamcinolone injection on refractory diabetic macular edema | |
| RU2659144C1 (ru) | Способ лечения катаракты у больных с активными неоваскулярными заболеваниями макулы | |
| JP2020518626A (ja) | 加齢黄斑変性による地図状萎縮に対し使用するためのブリモニジンおよび臨床試験デザイン | |
| HK40038783A (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| Kulkarni et al. | Corticosteroid therapies in the management of macular edema secondary to retinal vein occlusion | |
| Augustin et al. | Suprachoroidal drug delivery–a new approach for the treatment of severe macular diseases | |
| HK1228770B (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| HK1228770A1 (en) | Methods of treatment of ocular conditions with a sustained drug delivery implant | |
| Teich | EX-PRESS glaucoma filtration device: Review of clinical experience and comparison with trabeculectomy5 | |
| Akman et al. | A Karalezli, M Borazan, C Kucukerdonmez | |
| HK1190092B (en) | Bevacizumab for use in a method for treating atrophic age related macular degeneration |